The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction

PHASE1CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

July 26, 2023

Study Completion Date

July 26, 2023

Conditions
Cardiovascular DiseasesCardiovascular Risk FactorVasoconstriction
Interventions
DRUG

BQ-788

This intervention is aimed at blocking endothelin type B receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min

DRUG

BQ-123

This intervention is aimed at blocking endothelin type A receptors to assess racial differences during vasoconstriction. The infusion rate will be 2 µl/min

DRUG

L-Arginine

A substrate that is administered to increase endogenous nitric oxide production. The infusion rate will be 2 µl/min

DRUG

NG Nitro L Arginine Methyl Ester

L-Name is a NOS inhibitor that is administered to each site to allow for the quantification of NO contribution to vasodilation. The infusion rate will be 2 µl/min

DRUG

Sodium Nitroprusside

SNP will be perfused through each site to induce maximal vasodilation. The infusion rate will be 2 µl/min

DRUG

Lactated Ringer's

Lactated Ringer will serve as the control site. The infusion rate will be 2 µl/min

Trial Locations (1)

76019

Science and Engineering Research and Innovation Building, Arlington

All Listed Sponsors
lead

The University of Texas at Arlington

OTHER

NCT03679780 - The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction | Biotech Hunter | Biotech Hunter